🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

676 results for “Solid” Clear

  1. KXV01 TCR Lentinvivo Injection

    TScan Therapeutics

    Advanced Solid Tumors

    phase 1 small molecule active

    2 trials

  2. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Cancer

    phase 1 small molecule active

    1 trial

  3. KXV01 TCR Lentinvivo Injection

    The First People's Hospital of Lianyungang

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  4. LCAR-C18S cells

    Nanjing Legend Biotech Co.

    Solid Tumors, Adult

    phase 1 mab terminated

    1 trial

  5. LOR-253 HCl

    Aptose Biosciences

    Advanced or Metastatic Solid Tumours

    phase 1 small molecule completed

    1 trial

  6. LY3039478

    Eli Lilly and Company

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  7. Lenalidomide (CC-5013)

    BRIGHT MINDS BIOSCIENCES INC.

    Advanced Solid Tumors

    phase 1 small molecule active

    1 trial

  8. Lifirafenib

    BEONE MEDICINES AUS PTY LTD

    Solid Tumor, Adult

    phase 1 small molecule completed

    1 trial

  9. Lipotecan

    Taiwan Liposome Company

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  10. Livmoniplimab, Budigalimab

    AbbVie Deutschland GmbH & Co. KG

    Locally Advanced or Metastatic Solid Tumors, Solid Tumors

    phase 1 small molecule active

    1 trial

  11. Lynparza 100 mg film-coated tablets, AZD2281, AZD2281, AZD2281

    AstraZeneca AB

    solid tumors

    phase 1 small molecule active

    1 trial

  12. M1774 (oral ATR inhibitor) in Combination with PLX038 (Topo1 inhibitor) with dose expansion cohorts in patients with advanced solid tumors

    The George Institute

    Patients with pretreated, metastatic or locally advanced cancer for the dose escalation part and dose expansion cohorts in patients with advanced triple-negative breast cancers and advanced cancers with ATM mutation.

    phase 1 other active

    1 trial

  13. M9466 Alone or in Combination in Advanced Solid Tumors (DDRiver 501)

    Merck Sharp and Dohme

    Advanced solid tumors

    phase 1 other active

    1 trial

  14. M9466 in Combination with Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511)

    Merck Sharp and Dohme

    Advanced solid tumors and colorectal cancer

    phase 1 other active

    1 trial

  15. MLN0128

    Takeda

    Advanced Solid Malignancies

    phase 1 small molecule completed

    2 trials

  16. MLN4924

    Takeda

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

  17. MLN4924

    Takeda

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  18. MLN7243

    Takeda

    Advanced Malignant Solid Tumors

    phase 1 small molecule terminated

    1 trial

  19. MNPR-101-DFO*-89Zr

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  20. MNPR-101-PCTA-177Lu

    Monopar Therapeutics

    Solid Tumor, Adult

    phase 1 small molecule active

    1 trial

  21. MPT0B640

    INTENSITY THERAPEUTICS, INC.

    Advanced Solid Tumor

    phase 1 small molecule terminated

    1 trial

  22. MRG007

    ArriVent BioPharma

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule active

    1 trial

  23. MSC2156119J

    Merck KGaA, Darmstadt, Germany

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  24. MVC-101

    Takeda

    Solid Tumour

    phase 1 mab terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources